Clinical trials: HIV Viremia
HIV, Acute HIV Infection
Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection
This is a multicenter, single arm, 96-week open-label study of the safety and virologic efficacy of fixed dose combination Dolutegravir/Lamivudine/Abacavir (DTG/3TC/ABC FDC) initiated during acute HIV infection (AHI).
- Trial name
- PHI-05 (NCT02384395)
- Testing
- Dolutegravir 50 mg, Lamivudine 300 mg, Abacavir 600 mg
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV -1 Infection, Antiretroviral Therapy
Impacts of HIV Treatment Regimens on Archived Drug Resistance
The study aims to determine the prevalence of drug resistance mutation (DRM) in virally suppressed HIV infection, and the impacts of regimen change and the presence of low level viremia.
- Conditions
- HIV -1 Infection, Antiretroviral Therapy, Drug Resistance, Microbial
- Trial name
- NCT07643948
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Chinese University of Hong Kong
Hiv
The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY
Antiretroviral therapy or ART blocks HIV replication reducing plasma viral loads to undetectable levels but has no effect on persistently infected cells in the body, called the virus reservoir.
- Trial name
- "TACKITON (NCT06823596)
- Testing
- Efavirenz 600mg
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- University of Toronto
HIV Infections
A Multicenter, Exploratory Study to Evaluate the Effects of Antiretroviral Cessation on Plasma Associated HIV-1 RNA
To evaluate viral load in the blood stream of HIV-infected patients during a 28-day washout following cessation of long-term zidovudine ( AZT ) therapy.
- Trial name
- NCT00000840
- Where
- 8 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Predictors of Time to Viremia With an Analytic Treatment Interruption
This is a two-center study of 30 HIV-infected participants who have been on antiretroviral therapy (ART) for at least two years.
- Trial name
- NCT03033017
- Testing
- Blood Testing
- Where
- 2 sites in United States
- Sponsor
- University of Minnesota
HIV
Emtricitabine/Tenofovir Alafenamide as Salvage ART
Background: HIV attacks the immune system. Antiretroviral therapy (ART) is a combination of drugs used for treating HIV infection. For some people, ART drugs stop working against their HIV.
- Trial name
- NCT02556333
- Testing
- FTC/TAF
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Seropositivity
Monitored Antiretroviral Pause in Chronic HIV-Infected Subjects With Long-Lasting Suppressed Viremia
Prospective, open-label, single arm, non-randomized, proof-of-concept study. Eligible patients will sign a written informed consent and will be followed-up at screening, baseline (ART interruption) and at 1, 2, 3, 4, 6, 8, 10…
- Trial name
- APACHE (NCT03198325)
- Testing
- Stop of ART
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- IRCCS San Raffaele
Acute HIV Infection, HIV Infections
HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine
Purpose: This is a pilot study to evaluate HIV viremia and persistence in acutely HIV infected antiretroviral naïve patients treated with Darunavir/ritonavir and Etravirine Participants: 20 participants, age 18 and older, HIV…
- Trial name
- NCT00855413
- Testing
- Darunavir, Ritonavir, Etravirine
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of North Carolina, Chapel Hill
Human Immunodeficiency Virus, Treatment Adherence
Data Science and Qualitative Research for Decision Support in the HIV Care Cascade
The goal of this study is to determine whether clinical prediction algorithms derived using statistical machine learning methods can be used to improve patient outcomes in large HIV care programs in sub-Saharan Africa and…
- Conditions
- Human Immunodeficiency Virus, Treatment Adherence, Treatment Compliance, Patient No Show
- Trial name
- CASCADE (NCT06604663)
- Testing
- Activation of the CDSS system
- Where
- Kenya
- Volunteers
- 80,000 people
- Sponsor
- Brown University
HIV Vaccine
Therapeutic Vaccine Based on aDC1 Dendritic Cells for the Control of Viremia After ATI in HIV Infected Individuals
The goal of this interventional study is to validate the strategy of adjuvant therapy with dendritic cells in HIV infection in chronically infected individuals.
- Trial name
- NCT05786937
- Testing
- Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides, Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides, Commercial ringer´s lactate solution
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- University of Sao Paulo General Hospital
HIV Infection
Intermittent vs. Continuous HAART to Treat Chronic HIV Infection
This study will evaluate the effects of intermittent short cycles of HAART (highly active antiretroviral therapy) for treating HIV infection.
- Trial name
- NCT00025909
- Testing
- Leukapheresis
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
HIV in Specific Parts of the Body of Patients Who Are Changing or Starting Potent Anti-HIV Drugs
The purpose of this study is to gain information on how the type and amount of HIV present in certain places in the body and in the blood are affected when potent (powerful) anti-HIV drugs are given.
- Trial name
- NCT00007488
- Where
- 23 sites in United States
- Volunteers
- 164 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
Background: Antiretroviral therapy (ART) has been able to improve the lifespan of individuals infected with human immunodeficiency virus type 1 (HIV-1), but ART requires continuous treatment that has substantial consequences on…
- Trial name
- NCT01295515
- Testing
- Pegylated Interferon Alpha 2b (PEGINTRON)
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Hiv, Transmission Vertical
Enhanced Mentor Mother Strategy for Pregnant and Postpartum Women Living With HIV
Mentor Mothers (MMs) are peer supporters who help pregnant and postpartum women living with HIV (WLHIV) as they receive prevention of mother-to-child transmission of HIV (PMTCT) services in resource-limited settings like Kenya.
- Conditions
- Hiv, Transmission Vertical, Viremia, Adherence, Treatment
- Trial name
- PIE-eMMs (NCT06999928)
- Testing
- Enhanced Mentor Mother Strategy
- Where
- Kenya
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Indiana University
HIV-1-infection
Genotype-Informed Versus Empiric Management of VirEmia
HIV infection can be effectively controlled with antiretroviral therapy (ART). However, children and adolescents living with HIV and receiving ART suffer high rates of treatment failure, predominantly caused by suboptimal…
- Trial name
- GIVE MOVE (NCT04233242)
- Testing
- Clinical management informed by HIV-1 genotypic resistance testing
- Where
- 10 sites in Lesotho, Tanzania
- Volunteers
- 286 people
- Sponsor
- Swiss Tropical & Public Health Institute
HIV Infections, Hepatitis B
Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection
This study will evaluate HIV-HBV infected individuals who have evidence of HBV replication in the blood after taking 48 weeks of more of the HBV active medication tenofovir in combination with emtricitabine or lamivudine.
- Trial name
- NCT00662545
- Testing
- Entecavir with continued standard of care antiretroviral therapy, continued standard of care with tenofovir in addition to emtricitabine or lamivudine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Discordant Immunological Response in HIV Infected Subjects
Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response
Phase I/IIClinical trial, proof of concept, double blind, and placebo-controlled, randomized 2:1 (MSCs: placebo), total sample size is 15 subjects
- Trial name
- NCT02290041
- Testing
- Infusion of MSC
- Where
- Spain
- Volunteers
- 5 people
- Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
HIV Infections
The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year
To determine, in HIV-infected patients, whether switching to a new soft gelatin capsule formulation of saquinavir or to indinavir following prolonged use of the original hard capsule formulation of saquinavir results in an acute…
- Trial name
- NCT00000848
- Testing
- Indinavir sulfate, Saquinavir
- Where
- 16 sites in United States
- Volunteers
- 144 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Effect of Anti-HIV Therapy (HAART) on HIV Levels in the Lungs and on Lung Cell Inflammation in HIV-Infected Patients
The purpose of this study is to see: (1) how the amount of HIV in the lungs compares to that in the blood; (2) if HAART reduces the amount of HIV in the lungs; and (3) if HAART reduces lung inflammation in HIV-infected patients.
- Trial name
- NCT00001110
- Testing
- Bronchoalveolar lavage
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
To evaluate changes in renal function, efficacy, and safety when switching from a combination of tenofovir/emtricitabine (TDF/FTC) plus a protease inhibitor/ritonavir (PI/r) to a combination of raltegravir (MK-0518) plus…
- Trial name
- RANIA (NCT02116660)
- Testing
- Raltegravir (MK-0518), Nevirapine, Lamivudine
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC